CAR T-cell structure, manufacturing, applications, and challenges in the management of communityacquired diseases and disorders

Abstract

This article discusses the groundbreaking potential of chimeric antigen receptor (CAR) T-cell therapy for cancer and its potential downsides. One intriguing method, CAR-modified T-cells, can target a specific cancer cell molecule. It has been gaining popularity worldwide, especially in hematological malignancies. However, resistance mechanisms, antigen loss, a suppressive tumor microenvironment, altered T cell trafficking, and metabolic competition may hinder therapeutic efficacy. Such infusion would improve patient care applications and enable the treatment of solid tumors and other tough diseases, transforming the immunotherapeutic landscape. Next-generation approaches that address present technology limitations are improving CAR T-cell therapy. The novel dual-targeting CAR model is being studied. This model can recognize many antigens, reducing tumor risk from antigen loss. To prepare T cells for success and durability, tumor modification methods are also being studied. In addition to being safer and more effective, CAR T-cell therapy may enable tailored and flexible cancer treatment approaches that could supplement or replace the current healthcare system and spur medical field change.